Immunosuppressants - Spain

Spain

In Spain, the revenue in the Immunosuppressants market is estimated to reach €0.46bn by 2024.
It is anticipated that the revenue will exhibit a Compound Annual Growth Rate (CAGR 2024-2029) of 14.62%, leading to a market volume of €0.91bn by 2029.
When compared globally, United States is expected to generate the highest revenue in the Immunosuppressants market, amounting to €32,550.00m by 2024.
Spain's immunosuppressant market is experiencing a surge in demand due to the country's high prevalence of autoimmune diseases.

Key regions: Australia, Germany, United Kingdom, United States, France

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Immunosuppressants in Spain has been steadily increasing over the years.

Customer preferences: Patients in Spain who have undergone organ transplants or are suffering from autoimmune diseases require immunosuppressants to suppress their immune system. The preference for branded drugs over generic drugs is high in Spain, and patients are willing to pay a premium for these drugs.

Trends in the market: The Immunosuppressants market in Spain has been growing at a steady pace due to the increasing prevalence of autoimmune diseases and organ transplantations. The market has been witnessing a shift towards biologics and biosimilars, which offer better efficacy and safety profiles compared to conventional immunosuppressants. The market is also witnessing an increase in the number of clinical trials for new immunosuppressants, which is expected to drive market growth in the coming years.

Local special circumstances: Spain has a well-established healthcare system that provides universal coverage to its citizens. The government has implemented policies to promote the use of generic drugs to reduce healthcare costs. However, the preference for branded drugs among patients has limited the growth of the generic immunosuppressants market in Spain.

Underlying macroeconomic factors: Spain has a high prevalence of autoimmune diseases, which has been driving the demand for immunosuppressants. The country has also been witnessing an increase in the number of organ transplantations, which has further fueled the demand for immunosuppressants. The aging population in Spain is also contributing to the growth of the market, as the incidence of autoimmune diseases is higher in older adults. The Spanish government has been investing in the healthcare sector, which has led to the development of advanced healthcare infrastructure and a skilled workforce. These factors have contributed to the growth of the Immunosuppressants market in Spain.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.